8-K: Myriad Genetics Secures $200 Million Senior Secured Credit Facility from OrbiMed

Myriad Genetics, a leader in molecular diagnostic testing, has closed a new five-year senior secured term loan credit facility of up to $200 million with OrbiMed to support its growth strategy and refinance existing debt.

Summary

• Myriad Genetics, Inc. entered into a $200 million senior secured term loan credit facility with OrbiMed Royalty & Credit Opportunities IV, LP on July 31, 2025.
• The facility includes an initial loan of $125 million, which was funded on the Closing Date.
• An additional $75 million is available as delayed draw loans at the company's election on or prior to June 30, 2027, with minimum draws of $25 million and increments of $5 million thereafter.
• The credit facility matures on July 31, 2030.
• Loans bear interest at a rate equal to the greater of the one-month SOFR Rate and 2.50%, plus an applicable margin of 6.50%.
• Scheduled principal payments of 2.50% of the unpaid principal amount commence on September 30, 2029, and quarterly thereafter.
• The proceeds will be used for working capital, general corporate purposes, and refinancing existing indebtedness, specifically replacing Myriad's previous ABL facility.
• The credit facility is secured by substantially all assets of Myriad Genetics and its material subsidiaries.
• An undrawn fee of 0.50% per annum is payable on the undrawn Delayed Draw Commitment Amount.

Sentiment

Score: 7

Explanation: The securing of a substantial credit facility provides Myriad Genetics with significant liquidity and financial flexibility, enabling it to pursue growth strategies and refinance existing debt. The partnership with a specialized healthcare investment firm like OrbiMed is a positive signal. However, the high interest rate and the comprehensive collateral package indicate a higher cost of capital and increased leverage, which introduces some financial risk. The revenue covenants also add a layer of performance pressure.

Positives

• Secured $200 million in new capital, providing significant liquidity and financial flexibility for the company's operations and growth.
• Refinances existing indebtedness, specifically replacing Myriad's previous ABL facility, which can streamline the company's debt structure.
• The partnership with OrbiMed, a leading global healthcare investment firm, provides financial backing and insights, potentially enhancing strategic capabilities.
• Access to an additional $75 million in delayed draw loans offers flexibility for future capital needs until June 30, 2027, without incurring immediate interest costs on the full amount.
• The new facility is explicitly stated to support the company's near-term objectives and long-term growth plan.

Negatives

• The credit facility is senior secured, meaning substantially all assets of Myriad Genetics and its material subsidiaries are pledged as collateral, increasing risk for other creditors and limiting unencumbered assets.
• The interest rate is SOFR + 6.50% with a 2.50% SOFR floor, which could be considered a relatively high cost of capital.
• Subject to customary mandatory prepayments from proceeds of indebtedness, certain asset sales, and casualty events, which could reduce available capital for other uses.
• A repayment premium applies to both voluntary and mandatory prepayments, increasing the cost of early debt reduction.
• The company is subject to a minimum trailing twelve-month revenue test, starting at $615 million and increasing to $974 million by December 31, 2029, which could limit operational flexibility if revenue targets are not met.

Risks

• **Financial Covenants**: Failure to comply with the minimum trailing twelve-month revenue test could trigger an Event of Default.
• **Cross-Defaults**: A default in payment or performance on other material indebtedness exceeding $10,000,000 could trigger an Event of Default under this credit facility.
• **Bankruptcy/Insolvency**: Standard bankruptcy or insolvency events for the company or any of its subsidiaries would constitute an Event of Default.
• **Material Judgments**: Any final judgment or order for the payment of money individually or in the aggregate exceeding $10,000,000 (exclusive of amounts fully covered by insurance) could lead to an Event of Default.
• **Change in Control**: A change in control event, as defined in the agreement, would trigger an Event of Default unless all Obligations are paid in full substantially concurrently.
• **Impairment of Security**: Any Loan Document or Lien granted thereunder on collateral valued at $7,500,000 or more ceasing to be effective, valid, binding, or a perfected first priority Lien could be an Event of Default.
• **Key Permit Events**: Termination or material amendment of any Key Permit or material rights/interests thereunder that would reasonably be expected to have a Material Adverse Effect.
• **Regulatory Matters**: Enforcement actions, warning letters, product recalls, or settlement agreements by regulatory authorities (e.g., FDA, CMS, EMA) exceeding $7,500,000 (or $10,000,000 for qui tam proceedings) could trigger an Event of Default.
• **General Business Risks**: Forward-looking statements are subject to known and unknown risks and uncertainties described in the company's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

The new credit facility provides Myriad Genetics with access to over $200 million in capital, which management expects to support the company's near-term objectives and long-term growth plan. Further details on the growth strategy are anticipated during the upcoming second quarter earnings call.

Management Comments

• "We are excited to partner with OrbiMed, a leading global healthcare investment firm. We value their insight and financial backing, which supports our ability to pursue our near-term objectives and long-term growth plan." Scott Leffler, Chief Financial Officer, Myriad Genetics.
• "Between this credit facility and our cash and cash equivalents, we now have access to more than $200 million in capital to support the company’s growth strategy, which we will speak to in more detail on our upcoming second quarter earnings call." Scott Leffler, Chief Financial Officer, Myriad Genetics.
• "We are pleased to partner with Myriad to support the company’s growth strategy. We believe Myriad’s portfolio of diagnostic tests provide critical insights that enable healthcare providers to deliver better care to patients." Matthew Rizzo, General Partner, OrbiMed.

Industry Context

This financing event for Myriad Genetics, a molecular diagnostic testing and precision medicine company, reflects continued investor confidence in the healthcare sector, particularly in specialized diagnostic areas. The partnership with OrbiMed, a firm focused on healthcare investments, aligns with a trend of specialized capital providers supporting growth in the life sciences and medical technology industries. The refinancing of an existing ABL facility suggests a strategic move to optimize the capital structure for long-term growth, a common practice among established companies in the competitive diagnostics market.

Comparison to Industry Standards

• The interest rate (SOFR + 6.50% with a 2.50% floor) is typical for senior secured term loans provided by specialized healthcare credit funds like OrbiMed, especially for companies in the molecular diagnostics space which can carry higher perceived risk due to R&D intensity and regulatory hurdles.
• The five-year maturity (July 31, 2030) is a standard term for such facilities, providing medium-term stability for the company's financial planning.
• The use of substantially all assets as collateral is customary for senior secured debt in this industry, similar to facilities provided to peers like Exact Sciences or Guardant Health, though specific terms would vary by company financial health and growth stage.
• Revenue covenants are common in credit agreements, and the specific thresholds ($615M rising to $974M) would need to be benchmarked against Myriad's historical performance and analyst consensus for future revenue growth to assess their stringency relative to industry peers.
• The ability to draw additional capital ($75M delayed draw) is a flexible feature often seen in growth-oriented companies, allowing them to access funds as needed without incurring immediate interest costs on the full amount.

Stakeholder Impact

• **Shareholders**: The new credit facility provides capital for growth and debt refinancing, potentially supporting long-term value creation, but also introduces increased leverage and a higher cost of debt. The comprehensive collateral package means shareholders' equity is subordinate to this debt.
• **Employees**: The stable financing can ensure continued operations and product development, which could provide job stability and opportunities.
• **Customers/Suppliers**: Stable financing can ensure continued operations and product development, benefiting customers and maintaining supplier relationships.
• **Creditors**: Existing ABL facility creditors are being refinanced. The new facility creates a senior secured position for OrbiMed, impacting the recovery prospects of other unsecured creditors in a default scenario.

Next Steps

• Myriad Genetics will provide more details on its growth strategy during its upcoming second quarter earnings call.
• The company may elect to draw the additional $75 million in delayed draw loans on or prior to June 30, 2027.
• Scheduled principal payments on the loans will commence on September 30, 2029.
• The company must comply with a minimum trailing twelve-month revenue test, starting December 31, 2025, and increasing quarterly.
• Ongoing compliance with various financial and operational covenants, including maintaining security interests and providing regular financial reports.

Key Dates

Recommendation

The new $200 million credit facility provides Myriad Genetics with crucial liquidity and the ability to refinance existing debt, which are positive steps for operational stability and pursuing growth initiatives in the competitive molecular diagnostics market. The partnership with OrbiMed, a specialized healthcare investor, lends credibility. However, the terms include a relatively high interest rate and a comprehensive security package, indicating a higher cost of capital and increased leverage. The revenue covenants introduce performance pressure. While the financing addresses immediate capital needs and supports strategic plans, the associated costs and financial obligations suggest a 'hold' recommendation. Investors should monitor the company's ability to meet revenue targets and effectively deploy the capital for profitable growth before considering a 'buy' or 'sell' position.

Keywords

Myriad Genetics, MYGN, OrbiMed, Credit Facility, Term Loan, Senior Secured Debt, Molecular Diagnostics, Precision Medicine, Healthcare Investment, Refinancing, Corporate Finance, SEC Filing, 8-K, Debt Financing, SOFR, Financial Covenants, Collateral, Liquidity